3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
25
Kidney Neoplasms
6
Neoplasms
5
Neoplasm Metastasis
4
Clear-cell metastatic renal cell carcinoma
4
Uterine Cervical Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Melanoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Kidney Diseases
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Interventions
Sunitinib
2
spartalizumab
1
pembrolizumab
1
palbociclib
1
enzalutamide
1
bicalutamide
1
avelumab
1
aldesleukin
1
Specimen Handling
1
Receptors, Androgen
1
Leuprolide
1
Interleukin-2
1
Health Information Exchange
1
Goserelin
1
Flutamide
1
Blood Specimen Collection
1
Axitinib
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Diseases
×
Axitinib
×
1 year
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA